These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 35390793)

  • 1. Antibody and Cellular-Based Therapies for Pediatric Acute Lymphoblastic Leukemia: Mechanisms and Prospects.
    Li W; Zhang Y; Kankala RK; Zou L; Chen Z
    Pharmacology; 2022; 107(7-8):368-375. PubMed ID: 35390793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody and cellular immunotherapies for acute lymphoblastic leukemia in adults.
    Kimble EL; Cassaday RD
    Leuk Lymphoma; 2021 Dec; 62(14):3333-3347. PubMed ID: 34402732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia.
    DasGupta RK; Marini BL; Rudoni J; Perissinotti AJ
    J Oncol Pharm Pract; 2018 Sep; 24(6):453-467. PubMed ID: 28583018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors.
    Aldoss I; Bargou RC; Nagorsen D; Friberg GR; Baeuerle PA; Forman SJ
    Leukemia; 2017 Apr; 31(4):777-787. PubMed ID: 28028314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Moving immunotherapy into the front line in ALL.
    Winters A; Gore L
    Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):209-217. PubMed ID: 31808875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progress and Innovations in the Management of Adult Acute Lymphoblastic Leukemia.
    Jabbour E; Pui CH; Kantarjian H
    JAMA Oncol; 2018 Oct; 4(10):1413-1420. PubMed ID: 29931220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The future of cellular immunotherapy for childhood leukemia.
    Bonifant CL; Tasian SK
    Curr Opin Pediatr; 2020 Feb; 32(1):13-25. PubMed ID: 31851053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Development and Therapeutic Applications of Bispecific Antibodies for Hematologic Malignancies.
    Hays P
    Cancer Treat Res; 2022; 183():287-315. PubMed ID: 35551665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bispecific antibodies in acute lymphoblastic leukemia therapy.
    Chitadze G; Laqua A; Lettau M; Baldus CD; Brüggemann M
    Expert Rev Hematol; 2020 Nov; 13(11):1211-1233. PubMed ID: 33000968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal antibodies and immune therapies for adult precursor B-acute lymphoblastic leukemia.
    Sikaria S; Aldoss I; Akhtari M
    Immunol Lett; 2016 Apr; 172():113-23. PubMed ID: 26921100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New targeted therapies for relapsed pediatric acute lymphoblastic leukemia.
    Pierro J; Hogan LE; Bhatla T; Carroll WL
    Expert Rev Anticancer Ther; 2017 Aug; 17(8):725-736. PubMed ID: 28649891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapies in acute leukemia.
    Boissel N; Rabian F
    Therapie; 2022; 77(2):241-250. PubMed ID: 34924207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current and future role of bispecific T-cell engagers in pediatric acute lymphoblastic leukemia.
    Algeri M; Del Bufalo F; Galaverna F; Locatelli F
    Expert Rev Hematol; 2018 Dec; 11(12):945-956. PubMed ID: 30358451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Humoral and cellular immunotherapy in ALL in children, adolescents, and young adults.
    Hochberg J; El-Mallawany NK; Cairo MS
    Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S6-13. PubMed ID: 25486958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of relapsed/refractory acute lymphoblastic leukemia.
    Paul S; Rausch CR; Nasnas PE; Kantarjian H; Jabbour EJ
    Clin Adv Hematol Oncol; 2019 Mar; 17(3):166-175. PubMed ID: 30969955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy in pediatric B-cell acute lymphoblastic leukemia.
    Wyatt KD; Bram RJ
    Hum Immunol; 2019 Jun; 80(6):400-408. PubMed ID: 30716352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pediatric Acute Lymphoblastic Leukemia Emerging Therapies-From Pathway to Target.
    Ivanov AV; Alecsa MS; Popescu R; Starcea MI; Mocanu AM; Rusu C; Miron IC
    Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36902091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia.
    Le Jeune C; Thomas X
    Drug Des Devel Ther; 2016; 10():757-65. PubMed ID: 26937176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in the treatment of acute lymphoblastic leukemia.
    Rafei H; Kantarjian HM; Jabbour EJ
    Leuk Lymphoma; 2019 Nov; 60(11):2606-2621. PubMed ID: 31092071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia.
    Danylesko I; Chowers G; Shouval R; Besser MJ; Jacoby E; Shimoni A; Nagler A; Avigdor A
    Curr Res Transl Med; 2020 Jan; 68(1):17-22. PubMed ID: 31882377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.